Wyeth Cuts European Primary Care Sales Force By 25%
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite reductions, Wyeth said it has strengthened specialty sales efforts around products like Enbrel.
You may also be interested in...
Enbrel Deceleration Continues: Firm Cites End Of Oral Demo As New Speed Bump
The firm recently begun a rheumatology ad campaign for TNF inhibitor etanercept; a dermatology television ad is yet to come.
Wyeth Begins Recruitment Of Part-Time Sales Reps
Wyeth will begin to implement its plan to integrate part-time employees into its U.S. primary care sales force starting in late November
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.